All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Lung Cancer Management Methods Expand to Encompass Multiple Treatment Perspectives

April 14th 2022

New treatment methods in patients with small cell lung cancer and non–small cell lung cancer are on the horizon, with the introduction of combination immunotherapy, biomarker assays, and supportive oncology programs for patients and care partners.

Resistance to Noncovalent BTK Inhibitors Raises Questions Around Impact of Mutations in CLL

April 14th 2022

A small proportion of a subset of patients with chronic lymphocytic leukemia acquired mechanisms of genetic resistance to the novel noncovalent BTK inhibitor pirtobrutinib, according to results from a genomic analysis of patients in the phase 1/2 BRUIN trial.

Investigators Hope to Build on Early Efficacy in KRAS G12C-Mutated CRC

April 14th 2022

Investigators have explored the potential of KRAS inhibition in patients with colorectal cancer, and early results have established the pathway as a prime target for drug development.

Epcoritamab Elicits 63.1% ORR in Relapsed/Refractory Large B-cell Lymphoma

April 14th 2022

Epcoritamab was found to produce an encouraging overall response rate in patients with relapsed or refractory large B-cell lymphoma who previously received CAR T-cell therapy.

American Oncology Network and Low Country Cancer Care Expand to Waycross Georgia Opening New Office

April 14th 2022

American Oncology Network, LLC and its partner, Low Country Cancer Care, are pleased to announce the opening of their sixth cancer center located at 1206 Alice Street in Waycross, Ga. Medical oncologist and hematologist Dr. Asit Jha will be joining LCCC and practicing at this new site.

Research Efforts Seek to Further Explore the Potential of Uproleselan in AML

April 14th 2022

Tapan M. Kadia, MD, discusses what makes uproleselan unique from other agents under investigation in acute myeloid leukemia and sheds light on the many research efforts dedicated to further exploring its use in this disease.

Enfortumab Vedotin Approved in Europe for Locally Advanced or Metastatic Urothelial Cancer

April 13th 2022

The European Commission has approved enfortumab vedotin for use as a single agent in adult patients with locally advanced or metastatic urothelial cancer who have received prior platinum-containing therapy and a PD-1/L1 inhibitor.

Neoadjuvant Chemoimmunotherapy Demonstrates Activity in Advanced Ovarian Cancer

April 13th 2022

The addition of durvalumab and tremelimumab to chemotherapy led to encouraging responses and a suitable safety profile as neoadjuvant therapy in patients with advanced ovarian cancer, according to findings from the phase 2 KGOG 3046.

SOT101 Plus Pembrolizumab Elicits Encouraging Efficacy in Advanced Solid Tumors

April 13th 2022

The addition of SOT101, an interleukin-2/IL-15 Rβγ superagonist, to Pembrolizumab generated a clinical benefit and encouraging safety data in patients with advanced solid tumors.

Adebrelimab Plus Chemotherapy Improves Survival Vs Chemotherapy Alone in ES-SCLC

April 13th 2022

The addition of adebrelimab to chemotherapy elicited improved overall survival compared with chemotherapy and placebo in patients with extensive-stage small cell lung cancer.

Pembrolizumab Plus CG0070 Induces Promising Response Rates in BCG-Unresponsive NMIBC

April 13th 2022

The addition of the selective oncolytic adenovirus CG0070 to pembrolizumab showed encouraging activity and safety in Bacillus Calmette-Guerin–unresponsive non-muscle invasive bladder cancer, according to early data from the phase 2 CORE1 trial.

Frontline Canakinumab Triplet Misses Mark in Advanced NSCLC, But Shows Benefit in Select Subsets

April 13th 2022

The addition of canakinumab to frontline pembrolizumab and chemotherapy did not improve survival in previously untreated patients with locally advanced or metastatic non–small cell lung cancer. However, signals of activity were seen in patients with a baseline inflammatory biomarker high sensitivity-C-reactive protein.

FDA Authorizes IND Application for 177Lu-rhPSMA-10.1 for Metastatic Castration-Resistant Prostate Cancer

April 13th 2022

The FDA has cleared an investigational new drug application for 177Lu-rhPSMA-10.1 as a potential therapeutic option for patients with metastatic castration-resistant prostate cancer.

Sotigalimab Plus Pembrolizumab Elicits Broad Immune Activity in Metastatic Melanoma

April 13th 2022

The combination of the CD40 agonist antibody sotigalimab and pembrolizumab demonstrated a favorable safety profile and led to immunologic changes that correlated with clinical response in patients with unresectable stage III or IV metastatic melanoma.

TTX-030 Plus Budigalimab/mFOLFOX6 Induces Responses in PD-L1–Low Advanced Gastric/GEJ Cancer

April 12th 2022

The addition of the investigational anti-CD39 antibody TTX-030 to frontline treatment with the PD-L1 inhibitor budigalimab and mFOLFOX6 was determined to be safe and tolerable in patients with locally advanced or metastatic HER2-negative gastroesophageal junction adenocarcinoma.

Second-Line Nivolumab Plus Ipilimumab Improves PFS in Advanced Melanoma

April 12th 2022

The combination of nivolumab and ipilimumab demonstrated a statistically significant improvement in progression-free survival vs ipilimumab alone as second-line therapy in previously treated patients with stage III unresectable or stage IV melanoma.

BO-112 Plus Pembrolizumab Generates Responses in PD-1–Resistant Advanced Melanoma

April 12th 2022

The addition of BO-112 to pembrolizumab demonstrated efficacy and safety in patients with advanced melanoma who were resistant to anti–PD-1 therapies, according to final results from the phase 2 SPOTLIGHT203 trial.

Combination Navitoclax and Ruxolitinib Elicits Improved Bone Marrow Fibrosis in Myelofibrosis

April 12th 2022

Navitoclax plus ruxolitinib produced an improvement in bone marrow fibrosis and a reduction in variant allele frequency in patients with myelofibrosis who progressed on or had suboptimal response with prior ruxolitinib monotherapy.

MEDI5752 Demonstrates Intriguing Activity in Advanced Solid Tumors

April 12th 2022

MEDI5752 treatment led to a dose-dependent increase in peripheral T-cell proliferation and encouraging antitumor activity in patients with advanced solid tumors.

Addition of NG-641 to Nivolumab Under Exploration in Epithelial Tumors

April 12th 2022

The combination of the novel adenoviral vector NG-641 and nivolumab is being investigated in patients in the phase 1a/b NEBULA trial in patients with previously treated metastatic or advanced epithelial tumors.